A. Mark Fendrick, MD

Articles by A. Mark Fendrick, MD

Session 4: Discussant & Conclusion

September 5th 2013

Mark Fendrick, MD, co-editor-in-chief of The American Journal of Managed Care, concludes the PCDC event with his closing remarks.

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

ByMichael E. Chernew, PhD,Rick McKellar, BS,Wade Aubry, MD,Roy Beck, MD, PhD,Joshua Benner, PharmD, ScD,Jan E. Berger, MD, MJ,A. Mark Fendrick, MD,Felicia Forma, BSc,Dana Goldman, PhD,Anne Peters, MD,Rebecca Killion, MA,Darius Lakdawalla, PhD,Douglas K. Owens, MD,Joe Stahl, MA

July 2nd 2013

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

February 12th 2013

Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.

Inside Out: Reversing the Focus on Emergency Departments to Enhance Efficiency

ByAdam Sharp, MD, MS,A. Mark Fendrick, MD

January 21st 2013

We describe how shifting focus from those visiting the ED to those admitted to the hospital from the ED offers more potential for improving healthcare efficiency.

Transformation

ByJohn V. Cox, DO, MBA, FACP,A. Mark Fendrick, MD

May 10th 2012

Journal of Oncology Practice (JOP) and The American Journal of Managed Care (AJMC) join efforts to highlight work focusing on issues affecting payers and providers.

Putting Value Into Practice

ByA. Mark Fendrick, MD,Jonas de Souza, MD

March 12th 2012

Insights Into Value-Based Insurance Design in Oncology

Developing Dialogue in Healthcare

ByJohn V. Cox, DO, MBA, FACP,A. Mark Fendrick, MD

May 23rd 2011

The editors introduce this special issue, which contributes to an ongoing dialogue in cancer care that explores the tension between new therapeutics and the ever-increasing need to limit resources.

HIT Press Club AJMC - Dr. A. Mark Fendrick of the University of Michigan

ByA. Mark Fendrick, MD

March 28th 2011

Dr. A Mark Fendrick welcomes the participants to the Healthcare Innovations and HIT Q&A Session at the National Press Club.

In this commentary, our Co-Editors-in-Chief advocate valuebased principles that align incentives to encourage use of high value services as an important tool in healthcare reform.

The Co-Pay Connection - Dr. A. Mark Fendrick of the University of Michigan

ByA. Mark Fendrick, MD

January 2nd 2009

Dr. A. Mark Fendrick explains the concept of Value-Based Insurance Design (VBID) and how it works.

Coronary Artery Bypass Grafting in Octogenarians: Clinical and Economic Outcomes at Community-Based Healthcare Facilities

ByBrahmajee K. Nallamothu, MD, MPH,Sanjay Saint, MD, MPH,Kim A. Eagle, MD,Kenneth M. Langa, MD, PhD,A. Mark Fendrick, MD,Robert V. Hogikyan, MD,

August 1st 2002

Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day Makes

BySusan G. Blitz, MD, MPH,Peter Cram, MD,Michael E. Chernew, PhD,Arnold S. Monto, MD,A. Mark Fendrick, MD

March 1st 2002

A New Method for Determining Patient Payments for Outpatient Drugs

ByDana P. Goldman, PhD,A. Mark Fendrick, MD,Dean G. Smith, PhD,Michael E. Chernew, PhD

February 1st 2002

A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost

ByA. Mark Fendrick, MD,Dean G. Smith, PhD,Michael E. Chernew, PhD,Sonali N. Shah, MBA, MPH

September 1st 2001

A. Mark Fendrick, MD

Articles by A. Mark Fendrick, MD

Session 4: Discussant & Conclusion

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

Inside Out: Reversing the Focus on Emergency Departments to Enhance Efficiency

Transformation

Putting Value Into Practice

Developing Dialogue in Healthcare

HIT Press Club AJMC - Dr. A. Mark Fendrick of the University of Michigan

A Pharmacoeconomic Perspective on Stroke Prevention in Atrial Fibrillation

Value-Based Insurance Design: Embracing Value Over Cost Alone

Value Based Insurance Design: Maintaining a Focus on Health in an Era of Cost Containment

The Co-Pay Connection - Dr. A. Mark Fendrick of the University of Michigan

"Fiscally Responsible, Clinically Sensitive" Cost Sharing: Contain Costs While Preserving Quality

Value-based Insurance Design: Aligning Incentives to Bridge the Divide Between Quality Improvement and Cost Containment

The Role of Gastroprotection in Patients on NSAID Therapy

Rising Out-of-pocket Costs in Disease Management Programs

Value-based Insurance Design: A "Clinically Sensitive" Approach to Preserve Quality of Care and Contain Costs

Univariate Solutions in a Multivariate World: Can We Afford to Practice as in the "good old days"?

COX-2 Inhibitor Use After Vioxx: Careful Balance or End of the Rope?

Acute Exacerbation of Chronic Bronchitis: A Primary Care Consensus Guideline

Taking Stock at 2 Years - Continuing the Journey

Improving Cancer Screening Adherence: Using the "Teachable Moment" as a Delivery Setting for Educational Interventions

Mechanisms to Improve Pharmaceutical Use in Managed Care: To Study Controls, Control the Studies [Please]

Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience

Cost-Effective Use of NSAIDs: Issues Pertinent to Coxib Use in Managed Care

A Word From the New Editors

Coronary Artery Bypass Grafting in Octogenarians: Clinical and Economic Outcomes at Community-Based Healthcare Facilities

Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day Makes

A New Method for Determining Patient Payments for Outpatient Drugs

A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost

Trending on AJMC

Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD

FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause

GLP-1 Receptor Agonists May Improve Rheumatoid Arthritis Symptoms

Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD

Serum Spectroscopy Reveals Prognostic Risk Factors in CLL